Literature DB >> 10716769

Benign prognosis in idiopathic hyper-CK-emia.

J C Reijneveld1, N C Notermans, W H Linssen, J H Wokke.   

Abstract

We report on the long-term follow-up in 31 patients with idiopathic hyper-CK-emia. At referral, all patients underwent a neurological interview and examination. Ancillary investigations included an open muscle biopsy and electromyography (EMG) in almost all, and other ancillary tests in some patients. After a follow-up period of 7.2 (mean; range 4-18) years, 74% of the patients had a final evaluation. The most common complaints at referral were fatigue and myalgia. EMG and muscle biopsy demonstrated minor, non-diagnostic abnormalities in 30 and 71% of patients, respectively. At follow-up, the pattern and the number of complaints had not changed substantially. One patient developed a sensory polyneuropathy. Neurological abnormalities were absent in all other patients. In conclusion, long-term follow-up of patients with idiopathic hyper-CK-emia does not reveal clinical deterioration. It seems justifiable to refrain from routine long-term follow-up in these patients. Copyright 2000 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10716769     DOI: 10.1002/(sici)1097-4598(200004)23:4<575::aid-mus17>3.0.co;2-5

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  9 in total

1.  Single-fiber electromyography in hyperCKemia: the value of fiber density.

Authors:  D A Restivo; V Pavone; A Nicotra
Journal:  Neurol Sci       Date:  2011-11-09       Impact factor: 3.307

2.  Case report: hyperCKemia: a diagnostic dilemma.

Authors:  Douglas Klein
Journal:  Can Fam Physician       Date:  2005-02       Impact factor: 3.275

Review 3.  The clinical laboratory evaluation of the patient with noninflammatory myopathy.

Authors:  R L Wortmann; G D Vladutiu
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

4.  Asymptomatic hyperCKemia during a two-year monitoring period: A case report and literature overview.

Authors:  Spyridon Klinis; Athanasios Symeonidis; Dimitrios Karanasios; Emmanouil K Symvoulakis
Journal:  Biomed Rep       Date:  2016-11-30

5.  The Effect of Years-Long Exposure to Low-Dose Colchicine on Renal and Liver Function and Blood Creatine Kinase Levels: Safety Insights from the Low-Dose Colchicine 2 (LoDoCo2) Trial.

Authors:  Amber van Broekhoven; Niekbachsh Mohammadnia; Max J M Silvis; Jonathan Los; Aernoud T L Fiolet; Tjerk S J Opstal; Arend Mosterd; John W Eikelboom; Stefan M Nidorf; Charley A Budgeon; Elizabeth Byrnes; Willem A Bax; Jan G P Tijssen; Dominique P V de Kleijn; Peter L Thompson; Saloua El Messaoudi; Jan H Cornel
Journal:  Clin Drug Investig       Date:  2022-10-08       Impact factor: 3.580

6.  Hypertension risk in idiopathic hyperCKemia.

Authors:  Lizzy M Brewster; Sjoerd van Bree; Jaap C Reijneveld; Nicolette C Notermans; W M Monique Verschuren; Joseph F Clark; Gert A van Montfrans; Marianne de Visser
Journal:  J Neurol       Date:  2008-01-22       Impact factor: 4.849

Review 7.  Approach to asymptomatic creatine kinase elevation.

Authors:  Siamak Moghadam-Kia; Chester V Oddis; Rohit Aggarwal
Journal:  Cleve Clin J Med       Date:  2016-01       Impact factor: 2.321

8.  Follow-up of a large population of asymptomatic/oligosymptomatic hyperckemic subjects.

Authors:  Elisabetta D'Adda; Monica Sciacco; Maria Elisa Fruguglietti; Veronica Crugnola; Valeria Lucchini; Filippo Martinelli-Boneschi; Chiara Zecca; Costanza Lamperti; Giacomo Pietro Comi; Nereo Bresolin; Maurizio Moggio; Alessandro Prelle
Journal:  J Neurol       Date:  2006-06-13       Impact factor: 4.849

9.  Idiopathic Benign Hyper-CK-Emia.

Authors:  Prashant Kaushik; Anuradha Gonuguntla
Journal:  Int J Biomed Sci       Date:  2009-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.